Bijukchhe SM; Marchevsky NG; Kibengo F; Sharma AK; Basi R; Cantrell L; Chuke S; Curtis B; Diavatopoulos DA; Eordogh A; Gautam MC; Gurung M; den Hartog G; Kattel HP; Kc S; Kelly D; Kelly S; Li G; Maskey P; Morey E; Mujadidi YF; Mulondo DJ; Nareeba T; Nyantaro M; Ojha AR; Pokhrel B; Rajkarnikar S; Roberts A; Shrestha S; Smits G; Thapa SB; Van der Klis F; Voysey M; Basnet S; Elliott AM; Liu X; Shrestha S; Pollard AJ, 2026. Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials. Lancet Infect Dis.
Janani L; Munro APS; Wright A; Aley PK; Babbage G; Baxter D; Bawa T; Bibi S; Bula M; Cathie K; Chatterjee K; Cosgrove C; Enever Y; Galiza E; Goodman AL; Green CA; Harris M; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; McGregor AC; Minassian AM; Moore P; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Pacurar M; Palfreeman A; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Wright D; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Cornelius V; Lambe T; Heath PT; Liu X; Faust SN, 2025. Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial. J Infect 91(3):106576
Costa Clemens SA; Bibi S; Marchevsky NG; Aley PK; Cappuccini F; Davies SA; Gonzalez I; Kelly SC; Mujadidi YF; Pipolo Milan E; Schwarzbold AV; Sprinz E; Voysey M; Weckx LY; Wright D; Bansal H; Bergagård MAS; Isaacs AJ; Kelly EJ; Lan D; Morgan S; Shankar NK; Shoemaker K; Villafana TL; Lambe T; Green JA; Pollard AJ, 2025. Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil. Mayo Clin Proc Innov Qual Outcomes 9(4):100642
Chanda C; Kibengo F; Mutua M; Ogada F; Muturi-Kioi V; Akis Yildirim BM; Amondi M; Baines A; Basajja V; Borthwick N; Bosire K; Chambula E; Chetty P; Chinyenze K; Chirro O; Crook A; De Bont J; Fernandez N; Ejou P; Farah B; Glaze M; Gombe B; Gumbe A; Hayes P; Itwi S; Juma S; Kabarambi A; Kabengele C; Kafeero P; Kakande A; Kanungi J; Kidega W; King D; Mahira R; Malogo R; Matsoso M; Michelo C; Moyo A; Mugaba S; Mugenya I; Muhumuza P; Mujadidi YF; Muriuki M; Musale V; Mutua G; Muwowo M; Mwale F; Mwangi I; Nakimbugwe M; Namuyanja A; Nduati E; Nielsen L; Nyange J; Oino G; Okech B; Omosa-Manyonyi G; Otieno D; Palmer S; Phiri H; Ramko K; Rutishauser RL; Sayeed E; Sajabi R; Serwanga J; G-T Wee E; Wenden C; Cicconi P; Fast P; Gilmour J; Jaoko W; Kaleebu P; Kilembe W; Kuipers H; Sanders EJ; Hanke T, 2025. Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa. Lancet Microbe 6(6):101041
Qadri F; Khanam F; Zhang Y; Biswas PK; Voysey M; Mujadidi YF; Kelly S; Bhuiyan AI; Rajib NH; Hossen I; Rahman N; Islam S; Pitzer VE; Kim YC; Clemens JD; Pollard AJ; Liu X, 2024. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. Lancet 404(10461):1419-1429
Khaki JJ; Meiring JE; Thindwa D; Henrion MYR; Jere TM; Msuku H; Heyderman RS; Gordon MA; Giorgi E, 2024. Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods. Sci Rep 14(1):17164
Dyson ZA; Ashton PM; Khanam F; Chunga Chirambo A; Shakya M; Meiring JE; Tonks S; Karkey A; Msefula C; Clemens JD; Dunstan SJ; Baker S; Dougan G; Pitzer VE; Basnyat B; Qadri F; Heyderman RS; Gordon MA; Pollard AJ; Holt KE, 2024. Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study. Lancet Microbe 5(8):100841
Bijukchhe SM; Gurung M; Pokhrel B; Shakya M; Pant D; Maskey P; Maskey H; Dhakal B; Rajkarkinar S; Bista S; Voysey M; Mujadidi YF; Kim YC; Atherton R; Jones E; Mclean F; Shrestha S; Hill M; Nyland KT; Kelly S; O'reilly P; Sah GP; Basnyat B; Pollard AJ; Shrestha S, 2024. Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age. Vaccine 42(8):2018-2025
Lugar M; Eugster A; Achenbach P; von dem Berge T; Berner R; Besser REJ; Casteels K; Elding Larsson H; Gemulla G; Kordonouri O; Lindner A; Lundgren M; Müller D; Oltarzewski M; Rochtus A; Scholz M; Szypowska A; Todd JA; Ziegler AG; Bonifacio E, 2023. SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood. JAMA 330(12):1151-1160
Kelly S; Liu X; Theiss-Nyland K; Voysey M; Murphy S; Li G; Nyantaro M; Gurung M; Basnet S; Pokhrel B; Bijukchhe SM; Eordogh A; Gombe B; Kakande A; Kerridge S; Kimbugwe G; Kusemererwa S; Lubyayi L; Luzze H; Mazur O; Mujadidi YF; Nabukenya S; Nagumo WR; Nareeba T; Noristani R; O'Reilly P; Roberts A; Shah G; Shrestha S; Shrestha LP; Thapa SB; Kibengo FM; Sharma AK; Elliott A; Shrestha S; Pollard AJ, 2023. Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials. Trials 24(1):465
Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD, 2023. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. J Infect 87(3):230-241
Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN, 2023. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect 87(1):18-26
Liu X; Munro AP; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN, 2023. Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]. J Infect 86(5):540-541
Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD, 2023. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. J Infect 86(6):574-583
Voysey M; Flaxman A; Aboagye J; Aley PK; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Charlton S; Clutterbuck EA; Davies S; Dold C; Edwards NJ; Ewer KJ; Faust SN; Folegatti PM; Fowler J; Gilbride C; Gilbert SC; Godfrey L; Hallis B; Humphries HE; Jenkin D; Kerridge S; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Snape MD; Song R; Thomas KM; Ulaszewska M; Woods D; Wright D; Pollard AJ; Lambe T, 2023. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. Clin Exp Immunol 211(3):280-287
Fidler S; Fox J; Tipoe T; Longet S; Tipton T; Abeywickrema M; Adele S; Alagaratnam J; Ali M; Aley PK; Aslam S; Balasubramanian A; Bara A; Bawa T; Brown A; Brown H; Cappuccini F; Davies S; Fowler J; Godfrey L; Goodman AL; Hilario K; Hackstein CP; Mathew M; Mujadidi YF; Packham A; Petersen C; Plested E; Pollock KM; Ramasamy MN; Robinson H; Robinson N; Rongkard P; Sanders H; Serafimova T; Spence N; Waters A; Woods D; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Winston A; Hill AVS; Gilbert SC; Carroll M; Pollard AJ; Lambe T; Ogbe A; Frater J, 2023. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. Clin Infect Dis 76(2):201-209
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ, 2022. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study. Lancet Glob Health 10(10):e1494-e1504
Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD, 2022. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respir Med 10(11):1049-1060
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN, 2022. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis 22(8):1131-1141
Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN, 2022. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. J Infect 84(6):795-813
Ogbe A; Pace M; Bittaye M; Tipoe T; Adele S; Alagaratnam J; Aley PK; Ansari MA; Bara A; Broadhead S; Brown A; Brown H; Cappuccini F; Cinardo P; Dejnirattisai W; Ewer KJ; Fok H; Folegatti PM; Fowler J; Godfrey L; Goodman AL; Jackson B; Jenkin D; Jones M; Longet S; Makinson RA; Marchevsky NG; Mathew M; Mazzella A; Mujadidi YF; Parolini L; Petersen C; Plested E; Pollock KM; Rajeswaran T; Ramasamy MN; Rhead S; Robinson H; Robinson N; Sanders H; Serrano S; Tipton T; Waters A; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Screaton GR; Winston A; Hill AV; Gilbert SC; Carroll M; Pollard AJ; Fidler S; Fox J; Lambe T; Frater J, 2022. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight 7.
Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD, 2022. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 399(10319):36-49
Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN, 2021. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398(10318):2258-2276
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA, 2021. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 398(10318):2277-2287
Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ, 2021. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health 9(11):e1561-e1568
Clemens SAC; Folegatti PM; Emary KRW; Weckx LY; Ratcliff J; Bibi S; De Almeida Mendes AV; Milan EP; Pittella A; Schwarzbold AV; Sprinz E; Aley PK; Bonsall D; Fraser C; Fuskova M; Gilbert SC; Jenkin D; Kelly S; Kerridge S; Lambe T; Marchevsky NG; Mujadidi YF; Plested E; Ramasamy MN; Simmonds P; Golubchik T; Voysey M; Pollard AJ, 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nat Commun 12(1):5861
Feng S; Phillips DJ; White T; Sayal H; Aley PK; Bibi S; Dold C; Fuskova M; Gilbert SC; Hirsch I; Humphries HE; Jepson B; Kelly EJ; Plested E; Shoemaker K; Thomas KM; Vekemans J; Villafana TL; Lambe T; Pollard AJ; Voysey M, 2021. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27(11):2032-2040
Flaxman A; Marchevsky NG; Jenkin D; Aboagye J; Aley PK; Angus B; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Cicconi P; Clutterbuck EA; Davies S; Dejnirattisai W; Dold C; Ewer KJ; Folegatti PM; Fowler J; Hill AVS; Kerridge S; Minassian AM; Mongkolsapaya J; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Sheehan E; Smith H; Snape MD; Song R; Woods D; Screaton G; Gilbert SC; Voysey M; Pollard AJ; Lambe T, 2021. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398(10304):981-990
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD, 2021. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet 398(10301):675-684
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD, 2021. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398(10303):856-869
Frater J; Ewer KJ; Ogbe A; Pace M; Adele S; Adland E; Alagaratnam J; Aley PK; Ali M; Ansari MA; Bara A; Bittaye M; Broadhead S; Brown A; Brown H; Cappuccini F; Cooney E; Dejnirattisai W; Dold C; Fairhead C; Fok H; Folegatti PM; Fowler J; Gibbs C; Goodman AL; Jenkin D; Jones M; Makinson R; Marchevsky NG; Mujadidi YF; Nguyen H; Parolini L; Petersen C; Plested E; Pollock KM; Ramasamy MN; Rhead S; Robinson H; Robinson N; Rongkard P; Ryan F; Serrano S; Tipoe T; Voysey M; Waters A; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Screaton GR; Winston A; Hill AVS; Gilbert SC; Pollard AJ; Fidler S; Fox J; Lambe T, 2021. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 8(8):e474-e485
Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ, 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397(10282):1351-1362
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ, 2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397(10277):881-891
Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ, 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99-111
Gibani MM; Jin C; Shrestha S; Moore M; Norman L; Voysey M; Jones E; Blackwell L; Thomaides-Brears H; Hill J; Blohmke CJ; Dobinson HC; Baker P; Jones C; Campbell D; Mujadidi YF; Plested E; Preciado-Llanes L; Napolitani G; Simmons A; Gordon MA; Angus B; Darton TC; Cerundulo V; Pollard AJ, 2020. Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLoS Negl Trop Dis 14(10):e0008783
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ, 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396(10249):467-478
Valente Pinto M; O'Connor D; Galal U; Clutterbuck EA; Robinson H; Plested E; Bibi S; Camara Pellisso S; Hughes H; Kerridge S; Mujadidi YF; Findlow H; Borrow R; Snape MD; Pollard AJ, 2020. Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. Open Forum Infect Dis 7(5):ofaa143
.
